Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed.
At AACR 2024, Diakonos Oncology announced promising interim analysis of the Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021) showing substantially increased survival of glioblastoma multiforme (GBM) patients well beyond the expected median overall survival (mOS) of 12.7 months for patients receiving the standard of care (SOC).
Findin...
